Close Menu

Fluxion

NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

NEW YORK (GenomeWeb News) – Fluxion Biosciences said today it is collaborating with the Stanford University School of Medicine to develop tests to help tailor treatments for cancer patients.

NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.

Cellectricon has resumed an IP infringement suit it initially filed against Fluxion last summer.

The cell-analysis toolmaker inked agreements with distributors in Korea and Japan, and sold its first instrument in China.

The firm will use the Phase II grant to develop a high-throughput screening system.

The firm will use the funding to develop its microfluidic system for cancer diagnostics.

The Italian company will distribute the BioFlux platform in parts of Europe, the Mediterranean, and in North Africa.

New Products: Feb 27, 2009

Premium

Thermo Fisher Scientific, Promega, MatriCal Bioscience, Fluxion Biosciences

Pages

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.